Table 2.

Dates of approval and reimbursement of pembrolizumab

Indication	FDA approval	NICE, England	PBAS, Australia	The National Advisory Committee for the Basket of Health Services, Israel
2L after disease progression with chemotherapy with PD-L1 TPS ≥ 1%	October 2015	January 2017	(Rejected in 2016)	January 2018
1L monotherapy for TPS ≥ 50%	October 2016	June 2017	July 2018 (with PS 0–1)	January 2017
1L in combination with chemotherapy—non-squamous cell carcinoma	August 2018	January 2019	July 2019 (with PS 0–1)	January 2019
1L in combination with chemotherapy—squamous cell carcinoma	October 2018	September 2019	–	January 2019

FDA Food and Drug Administration, NICE The National Institute for Health and Care Excellence, PBAC Pharmaceutical Benefits Advisory Committee, 1L first line, 2L second line, PD-L1 programmed death-ligand 1, TPS tumor proportion score, PS performance score